Loading…
Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance
To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance. CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healt...
Saved in:
| Published in: | In vivo (Athens) 2019-09, Vol.33 (5), p.1615-1620 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c387t-33fefad2990fd63f8119a59a9715e3d74efd59d3752c6cca1a6715d9f757391a3 |
|---|---|
| cites | |
| container_end_page | 1620 |
| container_issue | 5 |
| container_start_page | 1615 |
| container_title | In vivo (Athens) |
| container_volume | 33 |
| creator | Choi, Se Young Lim, Bumjin Kyung, Yoon Soo Kim, Yunlim Kim, Bong Min Jeon, Byung Hee Park, Jae Chan Sohn, Young Woong Lee, Jae Hyuk Uh, Ji-Hyun Jang, Seongsoo Kim, Choung-Soo |
| description | To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance.
CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM.
The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM
Among those cases up-graded, three were EpCAM
In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p |
| doi_str_mv | 10.21873/invivo.11645 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6755012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2283108578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-33fefad2990fd63f8119a59a9715e3d74efd59d3752c6cca1a6715d9f757391a3</originalsourceid><addsrcrecordid>eNpVkUFP3DAQhS1EVRbokWvlI5dQTxzH8QUJRbQgrQRSQXCzjD1hXXljsJNI7a9vdpeichpr3qdnPz9CToCdldBI_s33k5_iGUBdiT2yAKmgkKJS-2TBStEUjYDHA3KY8y_GaslY-ZkccKgkVMAXJLU-2TGYwffP9G5cx0RbDIG2ceyHTH1Pb2cNN-cHP6zoMloT_B909DbFPJgBaWt6i4le9zaMbmuzihnpfe_m7YUd_IT055gm9CFs0GPyqTMh45e3eUTuv1_etVfF8ubHdXuxLCxv5FBw3mFnXKkU61zNuwZAGaGMkiCQO1lh54RyXIrS1tYaMPWsONVJIbkCw4_I-c73ZXxao7NziGSCfkl-bdJvHY3XH5Xer_RznHQthWBQzganbwYpvo6YB7322eImBcYx67JsOLBGyGZGix1q51_JCbv3a4DpbU9615Pe9jTzX_9_2zv9rxj-F9Z9knk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2283108578</pqid></control><display><type>article</type><title>Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance</title><source>Open Access: PubMed Central</source><creator>Choi, Se Young ; Lim, Bumjin ; Kyung, Yoon Soo ; Kim, Yunlim ; Kim, Bong Min ; Jeon, Byung Hee ; Park, Jae Chan ; Sohn, Young Woong ; Lee, Jae Hyuk ; Uh, Ji-Hyun ; Jang, Seongsoo ; Kim, Choung-Soo</creator><creatorcontrib>Choi, Se Young ; Lim, Bumjin ; Kyung, Yoon Soo ; Kim, Yunlim ; Kim, Bong Min ; Jeon, Byung Hee ; Park, Jae Chan ; Sohn, Young Woong ; Lee, Jae Hyuk ; Uh, Ji-Hyun ; Jang, Seongsoo ; Kim, Choung-Soo</creatorcontrib><description>To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance.
CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM.
The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM
Among those cases up-graded, three were EpCAM
In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001).
CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>DOI: 10.21873/invivo.11645</identifier><identifier>PMID: 31471413</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adult ; Aged ; Biomarkers, Tumor ; Biopsy ; Case-Control Studies ; Cell Count ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Neoplastic Cells, Circulating - pathology ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - therapy ; Reproducibility of Results ; Sensitivity and Specificity ; Watchful Waiting</subject><ispartof>In vivo (Athens), 2019-09, Vol.33 (5), p.1615-1620</ispartof><rights>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright 2019, International Institute of Anticancer Research 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-33fefad2990fd63f8119a59a9715e3d74efd59d3752c6cca1a6715d9f757391a3</citedby><orcidid>0000-0002-7464-3207</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755012/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755012/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31471413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Se Young</creatorcontrib><creatorcontrib>Lim, Bumjin</creatorcontrib><creatorcontrib>Kyung, Yoon Soo</creatorcontrib><creatorcontrib>Kim, Yunlim</creatorcontrib><creatorcontrib>Kim, Bong Min</creatorcontrib><creatorcontrib>Jeon, Byung Hee</creatorcontrib><creatorcontrib>Park, Jae Chan</creatorcontrib><creatorcontrib>Sohn, Young Woong</creatorcontrib><creatorcontrib>Lee, Jae Hyuk</creatorcontrib><creatorcontrib>Uh, Ji-Hyun</creatorcontrib><creatorcontrib>Jang, Seongsoo</creatorcontrib><creatorcontrib>Kim, Choung-Soo</creatorcontrib><title>Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance.
CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM.
The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM
Among those cases up-graded, three were EpCAM
In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001).
CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor</subject><subject>Biopsy</subject><subject>Case-Control Studies</subject><subject>Cell Count</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Watchful Waiting</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkUFP3DAQhS1EVRbokWvlI5dQTxzH8QUJRbQgrQRSQXCzjD1hXXljsJNI7a9vdpeichpr3qdnPz9CToCdldBI_s33k5_iGUBdiT2yAKmgkKJS-2TBStEUjYDHA3KY8y_GaslY-ZkccKgkVMAXJLU-2TGYwffP9G5cx0RbDIG2ceyHTH1Pb2cNN-cHP6zoMloT_B909DbFPJgBaWt6i4le9zaMbmuzihnpfe_m7YUd_IT055gm9CFs0GPyqTMh45e3eUTuv1_etVfF8ubHdXuxLCxv5FBw3mFnXKkU61zNuwZAGaGMkiCQO1lh54RyXIrS1tYaMPWsONVJIbkCw4_I-c73ZXxao7NziGSCfkl-bdJvHY3XH5Xer_RznHQthWBQzganbwYpvo6YB7322eImBcYx67JsOLBGyGZGix1q51_JCbv3a4DpbU9615Pe9jTzX_9_2zv9rxj-F9Z9knk</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Choi, Se Young</creator><creator>Lim, Bumjin</creator><creator>Kyung, Yoon Soo</creator><creator>Kim, Yunlim</creator><creator>Kim, Bong Min</creator><creator>Jeon, Byung Hee</creator><creator>Park, Jae Chan</creator><creator>Sohn, Young Woong</creator><creator>Lee, Jae Hyuk</creator><creator>Uh, Ji-Hyun</creator><creator>Jang, Seongsoo</creator><creator>Kim, Choung-Soo</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7464-3207</orcidid></search><sort><creationdate>20190901</creationdate><title>Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance</title><author>Choi, Se Young ; Lim, Bumjin ; Kyung, Yoon Soo ; Kim, Yunlim ; Kim, Bong Min ; Jeon, Byung Hee ; Park, Jae Chan ; Sohn, Young Woong ; Lee, Jae Hyuk ; Uh, Ji-Hyun ; Jang, Seongsoo ; Kim, Choung-Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-33fefad2990fd63f8119a59a9715e3d74efd59d3752c6cca1a6715d9f757391a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor</topic><topic>Biopsy</topic><topic>Case-Control Studies</topic><topic>Cell Count</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Watchful Waiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Se Young</creatorcontrib><creatorcontrib>Lim, Bumjin</creatorcontrib><creatorcontrib>Kyung, Yoon Soo</creatorcontrib><creatorcontrib>Kim, Yunlim</creatorcontrib><creatorcontrib>Kim, Bong Min</creatorcontrib><creatorcontrib>Jeon, Byung Hee</creatorcontrib><creatorcontrib>Park, Jae Chan</creatorcontrib><creatorcontrib>Sohn, Young Woong</creatorcontrib><creatorcontrib>Lee, Jae Hyuk</creatorcontrib><creatorcontrib>Uh, Ji-Hyun</creatorcontrib><creatorcontrib>Jang, Seongsoo</creatorcontrib><creatorcontrib>Kim, Choung-Soo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Se Young</au><au>Lim, Bumjin</au><au>Kyung, Yoon Soo</au><au>Kim, Yunlim</au><au>Kim, Bong Min</au><au>Jeon, Byung Hee</au><au>Park, Jae Chan</au><au>Sohn, Young Woong</au><au>Lee, Jae Hyuk</au><au>Uh, Ji-Hyun</au><au>Jang, Seongsoo</au><au>Kim, Choung-Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>33</volume><issue>5</issue><spage>1615</spage><epage>1620</epage><pages>1615-1620</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance.
CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM.
The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM
Among those cases up-graded, three were EpCAM
In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001).
CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>31471413</pmid><doi>10.21873/invivo.11645</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7464-3207</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2019-09, Vol.33 (5), p.1615-1620 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6755012 |
| source | Open Access: PubMed Central |
| subjects | Adult Aged Biomarkers, Tumor Biopsy Case-Control Studies Cell Count Humans Male Middle Aged Neoplasm Grading Neoplasm Staging Neoplastic Cells, Circulating - pathology Prostatic Neoplasms - diagnosis Prostatic Neoplasms - therapy Reproducibility of Results Sensitivity and Specificity Watchful Waiting |
| title | Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A01%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20Tumor%20Cell%20Counts%20in%20Patients%20With%20Localized%20Prostate%20Cancer%20Including%20Those%20Under%20Active%20Surveillance&rft.jtitle=In%20vivo%20(Athens)&rft.au=Choi,%20Se%20Young&rft.date=2019-09-01&rft.volume=33&rft.issue=5&rft.spage=1615&rft.epage=1620&rft.pages=1615-1620&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/10.21873/invivo.11645&rft_dat=%3Cproquest_pubme%3E2283108578%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-33fefad2990fd63f8119a59a9715e3d74efd59d3752c6cca1a6715d9f757391a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2283108578&rft_id=info:pmid/31471413&rfr_iscdi=true |